Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Baijin Life Science Holdings (OTCPK:MNNGF) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Baijin Life Science Holdings had a gross margin of -5.34% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Baijin Life Science Holdings Gross Profit Related Terms
Baijin Life Science Holdings Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Luxury Goods subindustry, Baijin Life Science Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baijin Life Science Holdings Gross Profit vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's Gross Profit distribution charts can be found below:
* The bar in red indicates where Baijin Life Science Holdings's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.86 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Baijin Life Science Holdings (MNNGF) has a Gross Profit of $0.86 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Baijin Life Science Holdings and its competitors.
Is Baijin Life Science Holdings' Gross Profit too high?
Baijin Life Science Holdings' current Gross Profit is $0.86 Mil. Overall, Baijin Life Science Holdings has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' Gross Profit compare to TPR?
Baijin Life Science Holdings' Gross Profit of $0.86 Mil can be compared against companies in the Retail - Cyclical industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Retail - Cyclical company?
A good Gross Profit depends on the Retail - Cyclical industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Baijin Life Science Holdings and its competitors. Baijin Life Science Holdings's current Gross Profit is $0.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, Baijin Life Science Holdings (MNNGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.10 — trading 100% above its estimated fair value. The current Gross Profit is $0.86 Mil. Baijin Life Science Holdings' overall GF Score™ is 26/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current Gross Profit is $0.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?
Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued.
The current stock price of $0.10 is trading 100% above its estimated GF Value™ of $0.05.
GuruFocus considers Baijin Life Science Holdings to be Significantly Overvalued.
Key valuation signals for MNNGF:
Gross Profit: $0.86 Mil
GF Value™: $0.05 vs. price of $0.10 (100% above fair value)
No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
26GF Score
Get the complete analysis for MNNGF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNNGF has been successfully added to your 
